Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $140.20.

A number of analysts have commented on NVO shares. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th.

Novo Nordisk A/S Stock Up 0.9 %

NVO stock opened at $86.41 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The stock’s 50 day simple moving average is $100.35 and its 200 day simple moving average is $119.04. The company has a market cap of $387.77 billion, a P/E ratio of 27.96, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors have recently modified their holdings of the business. Atlas Brown Inc. boosted its position in Novo Nordisk A/S by 33.4% in the fourth quarter. Atlas Brown Inc. now owns 5,130 shares of the company’s stock worth $441,000 after purchasing an additional 1,285 shares during the last quarter. Ridgewood Investments LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $58,000. A. D. Beadell Investment Counsel Inc. grew its position in Novo Nordisk A/S by 41.1% during the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company’s stock valued at $1,119,000 after buying an additional 3,787 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Novo Nordisk A/S by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock worth $24,988,000 after buying an additional 1,051 shares during the last quarter. Finally, ORG Partners LLC raised its position in Novo Nordisk A/S by 181.7% in the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock worth $86,000 after acquiring an additional 647 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.